Atika Capital Management LLC
Source: SEC Form 13F · as of Mar 2026Atika Capital Management LLC holds 17 biotech & pharma companies tracked by BioSniper, totaling $157.1M in value as of Mar 2026 (SEC Form 13F).
Companies held
17
Total value held
$157.1M
BioSniper AIPage evidence connected
Prepared research question
What matters most for ELI LILLY & Co (LLY)—catalysts, financial risk and supporting evidence?
Run cited research
Traceable citations · Unknowns marked
| Company | Shares | Value |
|---|---|---|
| LLYELI LILLY & Co | 41,100 | $37.8M |
| TERNTerns Pharmaceuticals, Inc. | 300,720 | $19.6M |
| TEVATeva Pharmaceutical Industries Limited | 477,000 | $14.4M |
| COGTCogent Biosciences, Inc. | 293,200 | $11.3M |
| ORKAOruka Therapeutics, Inc. | 229,900 | $11.3M |
| DNTHDianthus Therapeutics, Inc. /DE/ | 128,800 | $10.8M |
| GHGuardant Health Inc. | 91,000 | $8.4M |
| UTHRUNITED THERAPEUTICS Corp | 12,350 | $7.3M |
| PTGXProtagonist Therapeutics, Inc | 62,100 | $6.5M |
| IMNMImmunome Inc. | 262,900 | $5.7M |
| DBVTDBV Technologies S.A. | 271,300 | $5.7M |
| XENEXenon Pharmaceuticals Inc. | 59,900 | $3.5M |
| MAZEMaze Therapeutics, Inc. | 111,500 | $3.3M |
| ABVXAbivax SA | 28,800 | $3.2M |
| ACHCAcadia Healthcare Company Inc. | 122,600 | $2.9M |
| KRYSKrystal Biotech, Inc. | 10,625 | $2.7M |
| BBIOBridgeBio Pharma, Inc. | 35,200 | $2.6M |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.